{
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "document": "Zimmerman_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 1
  },
  "completeness_stats": {
    "existing_evidence": 0,
    "new_evidence_found": 1,
    "total_evidence": 1
  },
  "verified_evidence": [],
  "new_evidence": [
    {
      "id": "comp_1",
      "quote": "because it is not subject to mutations to the A (H3 N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "relevance_explanation": "This quote supports the claim by explaining that recombinant technology avoids certain mutations that can limit the effectiveness of traditional (egg-based) vaccines, implying a broader and potentially more cross-protective immune response.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "model_used": "gpt-4.1"
}